The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This has only really spiked my interest again recently, but I won't be adding to my shares, I await an exit plan to present itself and I will do as such. But it's nice to be positive in general, makes the world lighter mate
Agree - I'm not 100% positive on this, far from it, but I do think now is a good time for breathing space and "relatively" low risk given the current SP and recent fundraising. We have a period of about 4-6 months IMO where developement news and sentiment could become much more positive, without the worry of funding. whist sentiment couldnt be lower.. Ive added quite a few over the past weeks, I will follow closely, but not waste time posting LSE etc
I like your positive attitude, investments are to be seen through, even at tough periods, you can't praise it and raise its expectations one moment, and condemn it and signal its demise another because your timeliness was not met.
I'm willing to give it time to breathe
Todays news is an interesting development - Direct to consumer via an intermedairy. I think we can expect more of these via other Health Testing suppliers for PSE. PSE Test certainly has an easier sales path than CIRT.
But I agree, the cash outflow for this company is stupidly high, certainly staff heavy and we're only talking board members, the scientists and lab members ain't excatly minimum wage. So I hope they have took there little hiatus from communication serious and come back with a return to somewhat credibility
There is a lot of ego in these spaces but with very little substance to them, so I appreciate the information when it's provided, and I feel instead of the measuring contests it would be nice to see a more debate or confer approach, note sharing as you could say. We're all invested, so I don't know why we do it
Fair point Dusty - I just find these boards painful, stopped using LSE and ADVFN all together as they are full of looons :0
H2 Cash used was about £3million - (H1 5.2 million) but within h2 we had the tax credit offset over the year to quite alarge capex, only 1/3 of Pact award reconised and very liitle from CIRT Revenue ...so balanced out I would say net cash burn of about £8.2 million year on zero sales on a clean sheet .Its hard to get a grip on what H1 will bring
staff costs will go up
PACT should come in
revenue for Cirt laggs by 3-5 months so should show a big improvement, would hope to see that at about £600k
plus PSE ?
So there alot of variables, However there is so much we dont have visibility of - Its all about confidence in the growth, but just as these boards were singing 600 tests a month prior to results, we now have the same posters with impending doom Jon lost alot of credability in my eyes, but its important to remember that taking a new product to market, getting Medicare code, labs etc in such a short time will be expensive and they have delivered alot operationally on target in a very short period of time..anyone who though BUPA sales would churn through in months post signing is detached from reality .. however in this finaical year they should start to shown some traction GLA.. time will tell.
That's dug 😒
Dug
This is what I meant by repeatedly saying the same thing.
Nearly all your posts are about cash running out, a bigger trail is needed, competing tests and Transform.
I get your points and I'm sure others do as well but you are just regurgitating the same information over and over again. Lol.
And the whole world and his wife knows that the PSE test was always designed to be run in parallel with a PSA test....yet again you completely misread my comment to suit your agenda.
Not what I actually said though is it.
Dissing the UK Transform Trial is like Betamax dissed VHS is what I said. The rest is history
@Newuncle combined with a PSA test is exactly how the PSE test works. So not news. Plus, from your earlier post - simply because one believes the best strategy is to pursue revenue today does not equate to “dissing” Transform. It is simply a difference of opinion.
And then there is this too:
Important Information
To book this test, you must have completed a PSA test within the last 6 months. If you have not done so, you can click here to book a Goodbody PSA test or you can add the PSA test through the checkout process.
This test is not available if you have received treatment for Prostate cancer within the last 4 weeks.
Feck Me have seen the price they charge for one PSE Test
EpiSwitch PSE Advanced Blood Test £905.00
We finally get some news, and things happening.
Do we really have to play who has the bigger manhood game?
Which mug is correct malarkey?
It's just idiotic, or I'll just post idiotic things till we do
Another placement is inevitable and you only need to look at working capital Vs burn rate to see it won't be long coming.
As for the recent RNS's about Goodbody and the London Clinic, both have had 'access' to the test since it was first made available to private patients. There is nothing new of commercial significance in these announcements. It is 8 months since a similar 'agreement was made with BUPA who are by far the largest private healthcare provider in the UK. Indeed that announcement said CiRT was to be offered to all BUPA patients being considered for immunotherapy. That definitive statement has since morphed into announcements of seminars intended to convince BUPA doctors to use CiRT. I wonder how many CiRT tests have been sold resulting from the BUPA agreement. Some might be wise to remind themselves that an agreement to provide access does not equate to a sales contract.
Interestingly Goodbody already offer a prostate test based on genetic analysis of saliva. It is 30% the price of PSE.
https://health.goodbodyclinic.com/product/prostate-cancer-dna-test/
Finally a few should educate themselves about Transform. Remember this is the trial Burrows said it was 'crucially were involved in
The 1st stage of Transform starts in less than a year and will quickly make 12500 blood samples available for testing. It would fast track regulatory approval which even OBD acknowledge to be critical for successful commercialisation. The only alternative is for OBD to self finance a randomised control trial at scale. Now that would require a placing that, to coin a well known phrase, will make the pips squeak'.
Thewombat,
fwiw I see today's RNS as much needed GOOD NEWS for OBD. Getting on board for testing is a decent achievement. But, nobody the terms of the deal (ie price per test or the volumes or how it will be rolled out). It should at least give hope that the tests are being adopted in the UK private sector. If the numbers were good then OBD would see revenues very early and have to issue a trading update on the back of them, time will tell as they say.
Dissing the UK Transform Trial is like the way Betamax dissed VHS Video Recorders back in the day.........
Morning -Not posted for some time - I couldn't take reading Dug's rambing's of a mug punter :) The guy doesnt know his own mind.
I think we are starting to see some traction and whilst I was very dissapointed with the numbers in Q2, and the squirmy presentation. That has to be put into context against the timeline and type of products we are dealing with. OBD have been very quiet on the publicity front, I think Jon took a big Slap off Major Shareholders an they are hopefully getting on with what they need to do.. The evidence case progress ofr CIRT is important and hopefully soom we will get some more deal following through. However confidence has been knocked and dont see the SP doing much positive or negative until some meat is put on the bones - I didnt expect much from BUPA last year and TBF neither did OBD, they stated that back in March 23, So now its a case of seeing how this pans out. If you take the immotion out of it sub 8p is a good entry point if you believe in the story.
With regards to Transform - I really dont care, Its a typical lethargic trial that will be outpaced by developements and IMO is the last thing we need to be throwing money at.. Jurys out for now. Good Luck All
@Newuncle I don’t think anyone disagrees with you. The problem is that jam tomorrow simply will not work for OBD. They desperately need revenue today and that is where their efforts are and should be.
Some , if not all will be buys.
Meant but
WILL buy alf buy i wait for cash raise
Seems to be a flurry of good news but lots of sell trades, you don't think the bods are talking this up so as to action another placement. I've seen this rather unscrupulous activity before with other Aim stocks.